Ascletis Pharma (HKG:1672) posted promising Phase Ib trial results in the U.S. for ASC30, a potential first-in-class GLP-1 receptor agonist for treating obesity, according to a Monday filing with the Hong Kong bourse.
A single subcutaneous injection of ASC30 showed a 36-day half-life, supporting once-monthly dosing. The oral tablet form of ASC30 also demonstrated "6.3% weight loss in patients with obesity after a four-week treatment."
Ascletis holds global patent protection until 2044 for ASC30.
The pharmaceutical shares were up by 5.8%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。